Effectiveness of the Inactivated COVID-19 Vaccine (CoronaVac) in Adult Population in Bali, Indonesia

Anton Suryatma[1]*, Raras Anasi[1], Miko Hananto[1], Asep Hermawan[1], Ririn Ramadhany[2], Irene Lorinda Indalao[2], Agustiningsih Agustiningsih[2], Ely Hujjatul Fikriyah[1], Teti Tejayanti[1], Rustika Rustika[3], Kristina Lumban Tobing[1], Ketut Suarjaya[4], I Wayan Widia[4], Pandji Wibawa Dhewantara[1]*

[1] Center for Research and Development on Public Health Effort, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560, Indonesia

[2] Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560, Indonesia

[3] Center for Research and Development on Humanities and Health Management, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560, Indonesia

[4] Bali Provincial Health Office, Jl. Melati No. 20, Denpasar 80233, Indonesia

*Authors contributed equally

Correspondence: Anton Suryatma, MD, MPH., Center for Research and Development of Public Health Effort, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia, Jakarta, 10560, Indonesia. Email: drantonsuryatma@gmail.com

Abstract

Background: Inactivated SARS-CoV-2 vaccine has been included in the national COVID-19 vaccination program in Indonesia since January 2021. The study aims to estimate the effectiveness of CoronaVac vaccine in preventing SARS-CoV-2 infection, hospitalization, and death in adult population aged ≥18 years in Bali, Indonesia.

Methods: Test-negative, case control study was conducted by linking SARS-CoV-2 laboratory records, COVID-19 vaccination, and health administrative data for the period of January 13 to June 30, 2021, among adults aged ≥18 years in Bali. Case-subjects were defined as individuals who had a positive RT-PCR test for SARS-CoV-2 during the period; they were matched with controls based on age, sex, district of residence, presence of comorbidities and week of testing. Conditional and multivariable logistic regression was performed to estimate adjusted vaccine effectiveness.

Results:

Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021 (Figure 1). Of which, 14,168 subjects were eligible for inclusion in the study. Total 5518 matched pairs were analyzed. Adjusted vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 infection was 14.5% (95% confidence interval -11 to 34.2) at 0-13 days after the first dose; 66.7% (58.1 to 73.5%) at ≥14 days after the second dose. Adjusted VE in preventing hospitalization and COVID-19-associated death was 71.1% (62.9% to 77.6%) and 87.4% (65.1% to 95.4%) at ≥14 days after receiving the second dose, respectively.

Conclusions: Two-dose of inactivated CoronaVac vaccine showed high effectiveness against laboratory confirmed COVID-19 infection, hospitalization, and death associated with COVID-19 among adults aged ≥18 years.

Keywords: inactivated vaccine, COVID-19, effectiveness, test-negative, Indonesia

Introduction

Indonesia rolled-out the first phase of mass vaccination program on January 13th, 2021, using the inactivated SARS-CoV-2 CoronaVac vaccine (Sinovac Life Sciences, Beijing, China). In the first phase, mass COVID-19 vaccination was targeting healthcare workers and general population including adults and elderly. A phase 1/2 clinical trial in China indicated that CoronaVac was tolerable, with acceptable safety and immunogenicity, and therefore supported the conduct of a phase 3 clinical trial in three countries including Indonesia.[1] The efficacy of CoronaVac varied among the countries, ranging from 50.7% to 84% against SARS-CoV-2 infection.[2-4] In Indonesia, two doses of CoronaVac vaccine had an efficacy of 65.3% against COVID-19 illness after 14 days of injection; this supported the approval of emergency use authorization (EUA) by the Indonesia National Agency of Drug and Food Control (NADFC).[2,5]

Evidence regarding its effectiveness against SARS-CoV-2 infection, hospitalization, and death in the "real world" conditions have been reported in number of countries such as Chile, Turkey, and Brazil.[6,7] However, studies suggest that inactivated COVID-19 vaccine VE varies from region to region. In Indonesia, where inactivated vaccine has been given to the population, study on evaluating inactivated vaccine performance in preventing infection and severe outcomes still limited especially in adults aged ≥ 18 years. The objective of this study was to estimate vaccine effectiveness (VE) of inactivated CoronaVac vaccine against COVID-19 infection, hospitalization, and COVID-19-related death among adult aged ≥18 years in Bali.

Methods

Setting and design

Bali is a one of the popular tropical islands in Indonesia, with a total land area of 5780 km^2 and population of more than 4.3 million.[8] Mass COVID-19 vaccination using inactivated SARS-CoV-2 (CoronaVac) was initiated by the Ministry of Health of Indonesia on January 13, 2021, across Indonesia, including in Bali. As of July 31, 2021, COVID-19 vaccines have been given to 2.8 million (41.9%) of the targeted Balinese population. About 2.2 million people aged ≥18 years had received at least one dose of COVID-19 vaccines (Supplementary Figure S1); 1.2 million (43.1%) had received at least one dose of inactivated CoronaVac vaccine.[9] The observation was conducted during January 13 to June 30, 2021. During the study period, the incidence of COVID-19 was increased during January-February and

followed with a declining trend from March to June 2021. There was a sharp increase in incidence in July due to B.1.617.2 (Delta) variants (Supplementary Figure S2, Figure S3).

We conducted a record-based retrospective, test-negative, matched case control (1:1) study to evaluate the effectiveness of inactivated CoronaVac vaccine in preventing laboratory confirmed SARS-CoV-2 infection, among adults (aged ≥18 years) during January to June 2021. This test negative design was chosen due to several reasons. First, accessibility to individual data who were laboratory-tested for SARS-CoV-2 was feasible through the national surveillance system; second, it was cost-effective and allowed for faster results; and lastly, the design could better control for potential biases, including healthcare seeking behavior and access to COVID-19 testing.[10]

Data sources

We linked individual health electronic databases including SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) test results from the national laboratory testing database (New All Record), COVID-19 vaccination registry, and hospitalization claims, managed by the Ministry of Health of Indonesia, using unique national citizen identification number. Data with foreign identification number and driving license number were excluded. We also checked the consistency in identification number, name, date of birth and sex between these databases. Confirmatory SARS-CoV-2 PCR test was performed on naso and/or oropharyngeal swab specimens in COVID-19 reference laboratories.[11]

Selection of cases and matched controls

Cases were adults aged ≥18 years identified as those who had at least one COVID-19-like symptom (fever with body temperature documented at ≥38°C, chills, cough, shortness of breath, fatigue or malaise, sore throat, headache, runny nose, congestion, muscle aches, nausea or vomiting, diarrhea, abdominal pain, altered sense of smell or taste) and were tested RT-PCR positive for SARS-CoV-2, between January 13 to June 30, 2021; were not confirmed as positive for SARS COV2 in the last 90 days (about 3 months) before the index date; and those who did not receive any COVID-19 vaccines other than CoronaVac before sample collection. Controls were defined as those who had negative RT-PCR test results during the same period, irrespective for symptoms; and who did not receive any COVID-19 vaccines other than CoronaVac before sample collection. Cases and control were matched based on age, sex, district of residence and week of sample collection/testing.

Vaccination status

Vaccination status of the subjects was determined by referring to linked individual vaccination record and was determined based on their SARS-CoV-2 test date. Fully vaccinated cases and controls were defined as having two doses of CoronaVac ≥14 days before the sample collection date. Adults who received no single dose of CoronaVac vaccine were defined as unvaccinated and all other adults who received one dose ≥14 days before sample collection date were defined as partially vaccinated.

Statistical analysis

Unadjusted and adjusted odds of having received CoronaVac vaccine were estimated using conditional logistic regression. Odds ratios (ORs) and 95% confidence interval (CI) of vaccination in cases and controls was compared. Adjusted ORs were estimated from models including age (by year, as continuous) and presence of comorbidities and prior SARS-CoV-2 infection. There was a considerable proportion of missing data for comorbidities (79%). Multiple imputation was performed with considering for covariates (age, sex, residence) and outcome. Vaccine effectiveness (VE) was calculated as one minus the OR multiplied by 100%. [12] Subgroup analyses were performed to assess VE based on age group (i.e., aged 18-49 years vs. 50 years and older). Additional analysis was performed to estimate VE against secondary outcomes (hospitalization and death due to COVID-19) using multivariable logistic regression, accounting for covariates such as age, sex, district of residence, imputed presence of comorbidities and week of sample collection. All statistical analyses were conducted using STATA software version 15.0 (Stata Cooperation, College Station, Texas, USA).

Results

Study population

Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021 (Figure 1). Of which, 14,168 subjects were eligible for inclusion in the study. Of these, 2886 (20.4%) were having positive RT-PCR test for SARS-CoV-2 and 11,282 (79.6%) were tested negative for SARS-CoV-2 infection. From this, total 5518 (39%) subjects were defined as case-control pairs after matching.

Characteristics of the study population and matched case-control were presented in Table 1. The median age of the overall study population (n=14,168) was 50 years (interquartile range, 31-65 years); 50.8% were aged ≥50 years. Thirty percent (n=4259) resided in Denpasar city.

Thirty four percent (n=4863) had received full vaccination; 42.5% (n=6016) had not received vaccine. Those who receiving positive RT-PCR test results were appeared much older, males, had at least one comorbidity and unvaccinated.

Among the case subjects, about 40% of subjects having comorbidities. Based on vaccination status, 453 (16.4%) had received two doses of CoronaVac vaccine. Nineteen percent (n=535) case subjects had received the first dose of CoronaVac vaccine and about two-third (n=1771) were unvaccinated. While among the control subjects, half of the subjects (n=1485/2759) were unvaccinated. Twenty four percent had received two doses of CoronaVac vaccine.

Vaccine effectiveness

After adjusting for covariates, compared to unvaccinated adults, two-dose of CoronaVac improved protection against SARS-CoV-2 infection (VE: 66.7%; 95%CI: 58.1-73.5%) at ≥14 days after the second dose. Partial vaccination with CoronaVac was not significantly associated with a reduced risk of laboratory-confirmed SARS-CoV-2 infection (VE: 14.5%; 95%CI: -11 to 34.2) at 0-13 days after the first dose. CoronaVac VE against COVID-19 infection was reduced with increasing age; 66.6% to 84.2% in adults aged 18-49 years vs. 57.7% to 78.7% in adults aged ≥50 years (Supplementary Table S1).

The adjusted VE in preventing COVID-19-related hospitalization and death was 71.1% (95%CI: 62.9%-77.6%) and 87.4% (95%CI: 65.1%-95.4%), respectively, at 14 days after the second dose (Table 3). Partial vaccination was less protective against COVID-19-related hospitalization and death among people aged 18 and older (Supplementary Table S2). Vaccine effectiveness against hospitalization was higher 79.4% (95%CI: 70-85.9%) in group of people aged ≥50 years relative to people aged 18-49 years (65.8%; 95%CI:49.1-77%). Death due to COVID-19 was not significantly associated with full vaccination in people aged 18-49 years (VE:65.7%, 95%CI: -99.5% to 94.1%). This result could be happened due to an effect of small sample size and small number of events (mortality). Among older population, vaccine effectiveness was 90.6% (95%CI:61.5-97.7%) in preventing death due to COVID-19.

To address potential issues related to the small sample size and rare event or outcome, we conducted an additional analysis using study population (n=14,168) (Supplementary Table S3, Table S4). Overall, the vaccine effectiveness was 65.4% (95%CI: 59.5-70.4%) in preventing COVID-19 infection; 78.1% (95%CI: 73.6-81.9%) in preventing hospitalization; and 93.9% (95%CI: 85-97.6%) in preventing COVID-19-related death in adults aged 18 years or older at 14-days after second dose. The effectiveness against both hospitalization and death due to

COVID-19 was higher in that population aged 50 years or older (71.9% and 83.1%, respectively) compared to group of people aged 18-49 years (88.7% and 94.1%, respectively) (Supplementary Table S4).

Discussion

High proportion of inactivated vaccine of CoronaVac have been used in national COVID-19 vaccination program in Indonesia. So far, this is the first health record-based observational study on assessing 'real-world' COVID-19 vaccine performance against laboratory-confirmed SARS-CoV-2 symptomatic infection, hospitalization, and death in Indonesian population. The study showed that complete regimen of CoronaVac vaccine appeared to be protective against COVID-19 infection about 66.7% (58.1-73.5%) among Balinese adults aged ≥18 years, which is consistent with the results of phase III trial.[5] Yet, the effectiveness was reduced by age. Furthermore, vaccination with CoronaVac vaccine was highly effective in preventing COVID-19-associated hospitalizations and death. This demonstrates that CoronaVac vaccination could reduce the risk of development severe COVID-19, especially in older population.

Our 'real world' estimated VE against symptomatic COVID-19 infection was consistent with that randomized controlled trials of vaccine efficacy in Indonesia (65.3%; 95%CI: 20%-85.1%).[2] Yet, it was lower than that of vaccine efficacy reported in Turkey (83.5%; 95% CI: 65.4%-92.1%)[3] and higher than that efficacy reported from Brazil (51%; 95%CI: 36%-62%) at 14 days after the second vaccination.[13] Chilean cohort VE study involving general population aged ≥16 years old also demonstrated the VE was 65.9% (95%CI: 65.2%-66.6%) against COVID-19 infection. While a TND case control study in Brazil demonstrated that two dose regimens of CoronaVac was effective in reducing risk of symptomatic COVID-19 (46.8%; 95%CI: 38.7% to 53.8%) at ≥14 days after the second dose among older population aged ≥70 years.[7]

Our study showed that inactivated CoronaVac vaccine was also effective in preventing hospitalization and COVID-19-associated death. We estimated that CoronaVac vaccine was 71.1% for the prevention of hospitalization and 87.4% for the prevention of COVID-19-related death. None has reported CoronaVac VE estimates against these two outcomes in Indonesia. Our VE estimates are dissimilar to estimates that have been reported elsewhere. A cohort study in Chile among adults aged ≥16 years showed that CoronaVac vaccine was 87.5% (95% CI, 86.7 to 88.2) effective against hospitalization and 86.3% (95% CI, 84.5 to 87.9) effective against COVID-19–related death.[6,14] While a TND study in Brazil among elderly aged 70 years or older, CoronaVac was effective against COVID-19-related hospitalization (55.5%; 95%CI:

46.5% to 62.9%) and death (61.2%, 95%CI: 48.9% to 70.5%) at ≥14 days after the second dose, respectively.[7] This discrepancy might be due to several factors including variation in study population and design (e.g., targeted age group, sample size) and difference in risk of transmission or epidemiological setting (e.g., a TND study in Brazil was conducted when P.1 or Gamma variant was predominant).

The strengths of this study are that: i) we used comprehensive health administrative database including individual laboratory test results, vaccination data and hospitalizations which include information on date of sample collection, type of vaccine, date of vaccination, date of hospital admission and underlying conditions; (ii) the subjects were chosen based on a standard laboratory confirmation for SARS-CoV-2 results. Thus, biases due to misclassification from infection or vaccination status were implausible. These findings are important to fill the gap in our knowledge regarding the performance of inactivated CoronaVac vaccine in the real-world. However, our study has limitations. First, while we attempted to make a robust approach by adjusting for number of potential confounding factors, including age, sex, geography, week of testing (sample collection) and presence of comorbidities, there might be still unmeasured confounding factors that biased the VE estimates (e.g., behavioral risk factors, type of variants). Second, this study was retrieved data from January to June 2021, which was just before the peak of Delta variants (B.1.617.2) outbreaks. Hence, the VE estimates presented here is likely reflected vaccine performance before Delta and Omicron becoming predominant variant in the community. VE of CoronaVac against Delta and Omicron-related infection and severity might be different. Studies elsewhere have reported the effects of Delta variants on the COVID-19 vaccines performance.[15,16] Further research is required to evaluate the effectiveness of CoronaVac against the circulating VOCs.

Conclusions

The two-dose regimens of inactivated CoronaVac vaccine was effective in preventing COVID-19 infection, hospitalizations for COVID-19 and COVID-19-related death in adults aged 18 years or older. Full vaccination was significantly reduced the risk of severe outcomes especially among 50 years or older.

Author contributions

Study conceptualization: AS, PWD, RR (Ririn Ramadhany), MH. Methodology: AS, RA, RR (Ririn Ramadhany), MH, AH, EHF, PWD. Formal analysis: AS, RA, PWD, MH. Project

administration: AS, RA, RR (Rustika Rustika), TT, AA, KS, IWW. Data collection: AS, RA, EHF, AA, KS, ILI, IWW, PWD. Validation: AS, RA, PWD, AS, RR (Ririn Ramadhany), ILI, AA, RR (Rustika Rustika), KK, TT. Funding: AS, TT, MH. Writing (original draft): AS, PWD. Writing (review and editing): all authors.

Ethic statement

The protocol of the study was approved by the Health Research Ethics Committee, National Institute of Health Research and Development, Ministry of Health, Indonesia (LB. 02.01/2/KE.533/2021). The study was considered exempt from informed consent. No human health risks were identified.

Conflict of interest

The authors declare that they have no competing interests. Anton Suryatma, Raras Anasi, Miko Hananto, Asep Hermawan, Ririn Ramadhany, Irene Lorinda Indalao, Agustiningsih Agustiningsih, Ely Hujjatul Fikriyah, Teti Tejayanti, Rustika Rustika, Kristina Lumban Tobing and Pandji Wibawa Dhewantara are full-time researcher at the National Institute of Health Research and Development, Ministry of Health of Indonesia. Ketut Suarjaya and I Wayan Widia are full-time employees of Provincial Health Office in Bali. None of us received shares or any kind monetary compensation linked to the distribution of CoronaVac in Indonesia or have any share or financial interests in Sinovac Life Sciences or parent companies.

Data availability statement

The datasets used and/or analyzed during the current study are protected by the Ministry of Health of Indonesia and are unsuitable for public sharing. Interested parties can apply for the data by contacting the data center of the Ministry of Health of Indonesia. All data generated or analyzed during this study are included in this published article (and its Supplementary information files). Aggregate data on vaccination and COVID-19 incidence are publicly available at https://vaksin.kemkes.go.id/#/vaccines

Funding

This study was funded by the National Institute of Health Research and Development, Ministry of Health, Indonesia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the authors and not necessarily those of the Ministry of Health of Indonesia.

Acknowledgement

We would like to thank Dr. Anas Ma'ruf and team at the Center of Health Data and Information of Ministry of Health Indonesia, and Mr. Made Darmawan and Mr. Akbar Antony Siregar at the National COVID-19 Control and Economic Recovery Committee (KPC-PEN) for their assistance and support in collating the data. We would also like to thank the Director of Provincial Health Office of Bali and team for their support in the implementation of this study and permission to access COVID-19 surveillance data.

References

1. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The Lancet Infectious diseases.* 2021;21(2):181-192.
2. Indonesia National Agency of Drug and Food Control. Emergency Use Authorization - CoronaVac. In. Jakarta: Indonesia National Agency of Drug and Food Control 2021.
3. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet.* 2021;398(10296):213-222.
4. Palacios R, Patiño EG, de Oliveira Piorelli R, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. *Trials.* 2020;21(1):853-853.
5. Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. *Vaccine.* 2021;39(44):6520-6528.
6. Ministerio de Salud Gobierno de Chile. *Effectiveness of the inactivated CoronaVac vaccine against SARS-CoV-2 in Chile - Preliminary report.* Chile: Misterio de Salud;2021.
7. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. *BMJ (Clinical research ed).* 2021;374:n2015.
8. Provincial Bureau of Statistics of Bali. *Bali in Figure 2021*. Denpasar: Provincial Bureau of Statistics of Bali; 2021.
9. Ministry of Health of Indonesia. COVID-19 Vaccine Dashboard. 2021; https://vaksin.kemkes.go.id/#/vaccines. Accessed 3 August 2021, 2021.
10. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. *Vaccine.* 2021;39(30):4013-4024.
11. Ministry of Health of Indonesia. *Guidelines on COVID-19 Prevention and Control, 5th revision* Jakarta: Ministry of Health of Indonesia; 2020.

12. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. *Bull World Health Organ.* 1985;63(6):1055-1068.
13. World Health Organization. *Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (Interim Guidance 24 May 2021).* Geneva: World Health Organization; 2021.
14. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine.* 2021;385(10):875-884.
15. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med.* 2021;385(7):585-594.
16. Li X-N, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. *Emerg Microbes Infect.* 2021;10(1):1751-1759.



Figure 1. Flowchart for case and control selection

Table 1. Characteristics of the adults aged ≥18 years eligible in the study and case-control pairs included in the analysis

Characteristics	Total	Eligible study population		Matched pairs	
		Positive SARS-CoV-2 (n=2886)	Negative SARS-CoV-2 (n=11,282)	Cases (n=2759)	Controls (n=2759)
Age, years, median (IQR)	50 (31-65)	61 (45-69)	46 (30-64)	61 (45-69)	60 (41-70)
Age group, n (%)					
18-49 y	6969 (49.2)	853 (29.6)	6116 (54.2)	847 (30.7)	847 (30.7)
≥50 y	7199 (50.8)	2033 (70.4)	5166 (45.8)	1912 (69.3)	1912 (69.3)
Sex					
Male	7676 (54.2)	1730 (59.9)	5946 (52.7)	1648 (59.7)	1648 (59.7)
Female	6492 (45.8)	1156 (40.1)	5336 (47.3)	1111 (40.3)	1111 (40.3)
District of residence, n (%)					
Jembrana	564 (4)	87 (3)	477 (4.2)	75 (2.7)	75 (2.7)
Tabanan	1500 (10.6)	233 (8.1)	1267 (11.2)	233 (8.5)	233 (8.5)
Badung	2031 (14.3)	474 (16.4)	1557 (13.8)	465 (16.7)	456 (16.7)
Gianyar	1573 (11.1)	408 (14.1)	1165 (10.3)	363 (13.2)	363 (13.2)
Klungkung	554 (3.9)	79 (2.7)	475 (4.2)	73 (2.7)	73 (2.7)
Bangli	803 (5.7)	222 (7.7)	581 (5.2)	202 (7.3)	202 (7.3)
Karangasem	916 (6.5)	144 (5)	772 (6.8)	138 (5)	138 (5)
Buleleng	1968 (13.9)	353 (12.2)	1615 (14.3)	343 (12.4)	343 (12.4)
Denpasar	4259 (30.1)	886 (30.7)	3373 (29.9)	867 (31.4)	867 (31.4)
Reported No. of comorbidities, n (%)					
No	12,158 (85.8)	1698 (58.8)	10,460 (92.7)	1636 (59.3)	2473 (89.6)
Yes	2010 (14.2)	1188 (41.2)	822 (7.3)	1123 (40.7)	286 (10.4)
Vaccination status, n (%)					
Unvaccinated	6016 (42.5)	1867 (64.7)	4149 (36.8)	1771 (64.2)	1469 (53.3)
1st dose (0-13 days)	1001 (7.1)	222 (7.7)	779 (6.9)	216 (7.8)	193 (7)
1st dose (≥14 days)	1408 (9.9)	340 (11.8)	1068 (9.5)	319 (11.6)	272 (9.9)
2nd dose (0-13 days)	880 (6.2)	77 (2.7)	803 (7.1)	74 (2.7)	158 (5.7)
2nd dose (≥14 days)	4863 (34.3)	380 (13.2)	4483 (39.7)	379 (13.7)	667 (24.2)

Table 2. CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection in adults aged ≥18 years in Bali, Indonesia

Vaccination status	Cases	Controls	Vaccine effectiveness (95% CI)	
			Unadjusted	Adjusted*
Unvaccinated	1771 (64.2)	1469 (53.3)	Ref	Ref
0-13 days after 1st dose	216 (7.8)	193 (7)	22.9 (2.4- 39)	14.5 (-11 – 34.2)
≥14 days after 1st dose	319 (11.6)	272 (9.9)	24.1 (7.4-37.8)	10.5 (-12 – 28.6)
0-13 days after 2nd dose	74 (2.7)	158 (5.7)	67 (55.3-75.6)	63.1 (48.5-73.6)
≥14 days after 2nd dose	379 (13.7)	667 (24.2)	73.4 (78.4-67.2)	66.7 (58.1-73.5)

*Included covariates: age (as continuous), presence of comorbidities and prior SARS-CoV-2 infection

Table 3. CoronaVac vaccine effectiveness in preventing hospitalization and COVID-19-related death in adults aged ≥18 years in Bali, Indonesia

Vaccination status	Hospitalization		VE* % (95%CI)	Death		VE* % (95%CI)
	Yes (n=2490)	No (n=3028)		Yes (n=482)	No (n=5036)	
Unvaccinated	1932 (77.6)	1308 (43.2)	Ref	450 (93.4)	2790 (55.4)	Ref
0-13 days after 1st dose	124 (5)	285 (9.4)	28.3 (5.3-45.7)	10 (2.1)	399 (7.9)	53.9 (10-76.3)
≥14 days after 1st dose	218 (8.8)	373 (12.3)	34.1 (16.4-48.1)	15 (3.1)	576 (11.4)	58.6 (28.3-76.1)
0-13 days after 2nd dose	50 (2)	182 (6)	61.2 (42.6-73.7)	3 (0.6)	229 (4.6)	76 (22.9-92.5)
≥14 days after 2nd dose	166 (6.7)	880 (29)	71.1 (62.9-77.6)	4 (0.8)	1042 (20.7)	87.4 (65.1-95.4)

Abbreviations: VE, vaccine effectiveness; CI, confidence interval

*Adjusted by age (as continuous), sex, presence of comorbidities and prior SARS-CoV-2 infection, week of testing, district of residence

Supplementary file

Table S1. CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection in adults (aged ≥18 years), by age group, in Bali, Indonesia

Vaccination status	**Cases (n=2759)**	**Controls (n=2759)**	**VE % (95%CI)**	
			Unadjusted	**Adjusted***
Age group: 18-49 years (n=1694)				
Unvaccinated	247 (29.2)	95 (11.2)	Ref	Ref
0-13 days after 1st dose	133 (15.7)	122 (14.4)	57.2 (37.6-70.6)	48.3 (22.6-65.5)
≥14 days after 1st dose	144 (17)	131 (15.5)	65.7 (49.4-76.8)	55.1 (32-70.4)
0-13 days after 2nd dose	39 (4.6)	79 (9.3)	80.3 (68-87.9)	78.2 (63.6-87)
≥14 days after 2nd dose	284 (33.5)	420 (49.6)	82.2 (74.5-87.5)	77 (66.6-84.2)
Age group: ≥50 years (n=3824)				
Unvaccinated	1524 (79.7)	1374 (71.9)	Ref	Ref
0-13 days after 1st dose	83 (4.3)	71 (3.7)	-5 (-46.6–24.8)	-10.6 (-64.3–25.5)
≥14 days after 1st dose	175 (9.2)	141 (7.4)	-2 (-30 – 20)	-13.2 (-50.6 – 14.9)
0-13 days after 2nd dose	35 (1.8)	79 (4.1)	61.7 (42.3-74.6)	58.1 (32.4-74)
≥14 days after 2nd dose	95 (4.9)	247 (12.9)	74.3 (65.2-80.9)	69.9 (57.7-78.7)

*Included covariates: age (as continuous), presence of comorbidities and prior SARS-CoV-2 infection

Table S2. CoronaVac vaccine effectiveness in preventing hospitalization and death due to COVID-19 in adults (aged ≥18 years), by age group, in Bali, Indonesia (n=5518)

Vaccination status	**Hospitalization**		**VE*** **% (95%CI)**	**Death**		**VE*** **% (95%CI)**
	Yes (n=2490)	**No (n=3028)**		**Yes (n=482)**	**No (n=5036)**	
Age group: 18-49 years (n=1694)						
Unvaccinated	123	219	Ref	11	331	Ref
0-13 days after 1st dose	53	202	34.5 (-1-57.5)	0	255	NA
≥14 days after 1st dose	65	210	32.9 (-1.9-55.8)	1	274	78.7 (-84.6-97.6)
0-13 days after 2nd dose	16	102	64.9 (32.7-81.7)	1	117	51.3 (-330-94.5)
≥14 days after 2nd dose	99	605	65.8 (49.1-77)	2	702	65.7 (-99.5-94.1)
Age group: ≥50 years (n=3824)						
Unvaccinated	1809	1089	Ref	439	2459	Ref
0-13 days after 1st dose	71	83	14.1 (-28.1-42.4)	10	144	35.7 (-26.1-67.3)
≥14 days after 1st dose	153	163	34.7 (11.2-51.9)	14	302	57.2 (24.7-75.7)
0-13 days after 2nd dose	34	80	55.1 (26.5-72.6)	2	112	78.9 (12.7-94.9)
≥14 days after 2nd dose	67	275	79.4 (70-85.9)	2	340	90.6 (61.5-97.7)

Table S3. Assessment of CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection, hospitalization and death in adults aged ≥18 years in Bali, Indonesia, based on study population (n = 14,168)

Vaccination status	COVID-19 (n/N)	VE* % (95%CI)	Hospitalization (n/N)	VE* % (95%CI)	COVID-19-related death (n/N)	VE* % (95%CI)
Unvaccinated	1867/6016	Ref	2841/6016	Ref	574/6016	Ref
0-13 days after 1st dose	222/1001	6.7 (-12.1-22.3)	158/1001	27.9 (8.7-43.1)	10/1001	64.5 (31.6-81.5)
≥14 days after 1st dose	340/1408	-6.2 (-24.4-9.3)	336/1408	32 (17.4-44)	19/1408	62.9 (39.9-77.1)
0-13 days after 2nd dose	77/880	65 (54.7-72.9)	75/880	65.6 (53.3-74.7)	3/880	84.2 (50-95)
≥14 days after 2nd dose	380/4863	65.4 (59.5-70.4)	308/4863	78.1 (73.6-81.9)	5/4863	93.9 (85-97.6)

*Based on adjusted multivariable logistic regression, accounting for age (continuous), sex, district of residence, week of testing, presence of comorbidities, and prior infection.

Table S4. CoronaVac vaccine effectiveness in preventing hospitalization and death due to COVID-19 in adults (aged ≥18 years), by age group, in Bali, Indonesia based on the study population (n = 14,168)

Vaccination status	**Hospitalization**		**VE* % (95%CI)**	**Death**		**VE* % (95%CI)**
	Yes (n=3718)	**No (n=10,450)**		**Yes (n=482)**	**No (n=5036)**	
Age group: 18-49 years (n=1694)						
Unvaccinated	187	689	Ref	14	862	Ref
0-13 days after 1st dose	73	691	36 (8.2-55.4)	0	764	NA
≥14 days after 1st dose	109	749	35.8 (9.3-54.5)	1	857	88 (1.6-98.5)
0-13 days after 2nd dose	26	659	75.3 (59.4-85)	1	684	73.6 (-117.7-96.8)
≥14 days after 2nd dose	178	3608	71.9 (61.6-79.5)	2	3784	88.7 (36.5-98)
Age group: ≥50 years (n=3824)						
Unvaccinated	2654	2486	Ref	560	4580	Ref
0-13 days after 1st dose	85	152	12.9 (-22.6-38.1)	10	227	44.4 (-7.7-71.2)
≥14 days after 1st dose	227	323	26.6 (6.4-42.5)	18	532	57.8 (30.9-74.3)
0-13 days after 2nd dose	49	146	48 (21.8-65.4)	2	193	83.9 (34.1-96.1)
≥14 days after 2nd dose	130	947	83.1 (77.9-87.1)	3	1077	94.1 (81.4-98.1)

*Based on adjusted multivariable logistic regression, accounting for age (continuous), sex, district of residence, week of testing, presence of comorbidities, and prior infection.



Figure S1. COVID-19 vaccination coverage in adults ≥18 years (any type of vaccines) during January 13 to June 30, 2021, in Bali, Indonesia (Data source: Ministry of Health of Indonesia).



Figure S2. Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry of Health of Indonesia).



Figure S3. Distribution of SARS-CoV-2 variants of concern (VOCs) in samples examined during January to July 2021 in Bali, Indonesia. Variant proportions are estimated against total sequences of collected samples of each month. Total samples are varied for each month. Data are subject to change over time and will be updated as more data become available. Variant proportions may not represent national estimates. Analysis is based on data submitted by Indonesia Genomic Laboratory Surveillance Network as of 22 September 2021 (Data source: Ministry of Health of Indonesia).